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Abstract
Only few data on safety during high-dose, accelerated esca-
lation schedules during subcutaneous allergen immuno-
therapy (AIT) are available. The aim of this study was to as-
sess the safety and tolerability of an accelerated dose escala-
tion schedule of AIT in adult patients with moderate to 
severe seasonal rhinoconjunctivitis in a multicenter, open-
label, randomized phase II trial. The dose escalation scheme 
for patients in Group I (1 strength) included 3 injections with 
1 strength, B (10,000 TU/mL), whereas the dose escalation 
scheme for Group II (standard) included 7 injections with 2 
strengths, A (1,000 TU/mL) and B (10,000 TU/mL), of an alu-
minum hydroxide-adsorbed allergoid grass pollen prepara-
tion. Overall, 72 of 87 randomized patients (83.7%) reported 
at least 1 treatment-emergent adverse event (TEAE; 82.2 
[Group I] vs. 85.4% [Group II]); 58.8% of all reported TEAEs 
were assessed as being related to AIT (60.0 vs. 48.8%). The 
most frequently reported AIT-related TEAEs were swelling 
(46.7 vs. 34.1%), erythema (28.9 vs. 36.6%), and pruritus (31.1 
vs. 17.1%) at the site of the injection. Systemic allergic reac-
tions occurred in 5 (5.8%) patients overall, with more being 
reported in the 1-strength group (4 [8.9%] vs. 1 [2.4%]). All 
systemic allergic reactions were classified as World Allergy 
Organization (WAO) Grade 1 or Grade 2 reactions. Acceler-
ated high-dose escalation with an aluminum hydroxide-ad-
sorbed grass pollen allergoid can be initiated with a safety 
and tolerability profile comparable to the standard dose es-
calation schedule in patients with allergic rhinitis with or 
without asthma. © 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Allergic rhinitis (AR), although recognized as the most 
common form of allergy, is often underdiagnosed and in-
sufficiently treated. The prevalence of AR is estimated to 
be as high as 10–30% of the population, with the greatest 
frequency found in children and adolescents [1]. More-
over, AR is a systemic allergic disease with numerous co-
morbid disorders, including asthma, eczema, food aller-
gies, eosinophilic esophagitis (EoE), olfaction disorders, 
obstructive sleep apnea, and other symptoms [2].
Edited by: H.-U. Simon, Bern.
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Accelerated Dose Escalation of AIT Is Safe 
for AR Patients
95Int Arch Allergy Immunol 2020;181:94–102
DOI: 10.1159/000503684
Allergen-specific immunotherapy is highly effective in 
patients with AR and allergic asthma [3]; up to now, it is 
the only treatment that can modify the underlying course 
of allergic diseases [4]. One hallmark of subcutaneous im-
munotherapy (SCIT) is that increasing allergen doses are 
applied to reach the efficacious maintenance phase. How-
ever, only few data on the safety and tolerability of differ-
ent protocols of accelerated dose escalation are available. 
The efficacy of SCIT with grass pollen allergoids has been 
demonstrated in previous trials.
Corrigan et al. [5] demonstrated significant differenc-
es of 26.6 and 48.4% in symptom and medication score in 
the first and second year between active and placebo 
treatment, respectively, in favor of the grass pollen aller-
goid (p = 0.028 and 0.018). Recently, Chaker et al. [6] 
studied an accelerated dose escalation schedule with a 
grass pollen allergoid in 122 adult patients with AR with 
or without asthma. They demonstrated that the acceler-
ated 4-dose escalation scheme (starting with 200 thera-
peutic units [TU]) can be administered, with a favorable 
safety profile comparable to the standard 7-dose escala-
tion regime that starts with 100 TU. Of note, there were 
only mild systemic reactions in both groups with symp-
toms graded as World Allergy Organization (WAO) 
Grade 1 or 2.
Here, we aimed to go 1 step further, starting with an 
acceleration scheme of 3 injections and an initial dose of 
1,000 TU. We hypothesize that a further acceleration of 
dose escalation is possible, with a favorable safety profile 
and good tolerability. Moreover, accelerated dose sched-
ules might offer the opportunity to gain clinical and im-
munological tolerance faster than with standard dose es-
calation. In the long run, a reduction in the number of 
doctor’s visits and/or an improved tolerance might in-
crease compliance and adherence to SCIT in our patients. 
Therefore, the main objective of this therapeutic phase II 
trial was to evaluate the safety and tolerability of an ac-
celerated high-dose escalation schedule (1 strength) of 
specific immunotherapy with a grass pollen allergoid for 
adult patients with AR or rhinoconjunctivitis (with or 
without allergic asthma) caused by grass pollen, and com-
pare it to the standard specific immunotherapy with a 
2-strength grass pollen allergoid.
Material and Methods
Trial Design and Population
This was a multicenter, randomized, open-label, phase II clini-
cal trial in adult patients with moderate to severe AR or rhinocon-
junctivitis. It was conducted in Germany, Poland, Spain, and Rus-
sia. To be eligible for trial participation, patients had to meet the 
following inclusion criteria: an age between 18 and ≤65 years; IgE-
mediated seasonal AR or rhinoconjunctivitis with or without al-
lergic asthma, a positive skin prick test (≥3 mm in diameter) and 
specific IgE (≥0.70 kU/L) against grass pollen; at least 1 month of 
AR or rhinoconjunctivitis symptoms triggered by grass pollen ex-
posure in the period May to August; previous antiallergic treat-
ment for at least 2 seasons prior to enrollment; and written in-
formed consent. In cases with a diagnosis of asthma, the asthma 
had to be classified as “well controlled” according to the GINA 
guidelines [7]. Exclusion criteria were: a history of confirmed ana-
phylaxis after an AIT injection; AIT with grass pollen within the 
last 5 years; current treatment with any kind of immunotherapy; 
uncontrolled/partly controlled asthma according to the GINA 
guidelines; autoimmune diseases; β-blocker use; and a contraindi-
cation for the use of adrenalin.
Patients were randomized into an accelerated dose escalation 
group (Group I or “1-strength group”) and a standard dose escala-
tion group (Group II or “standard group”). The trial was conduct-
ed out of season in autumn and winter, i.e., prior to the grass pol-
len season. All patients were recruited between October and March 
2018 (the first patient on 4 October 2017 and the last patient on 31 
May 2018). No placebo group was included in this trial. EudraCT 
2017-000754-19.
Test Product and Treatment
The grass pollen allergoid (Allergopharma GmbH and Co., KG, 
Reinbek, Germany) was a mixture of allergens from 6 grass pol- 
len species (Holcus lanatus, Dactylis glomerata, Lolium perenne, 
Phleum pratense, Poa pratensis, and Festuca pratensis) which are 
chemically modified with formaldehyde. The allergoid is copre-
cipitated with aluminium hydroxide. The preparation is provided 
in 2 strengths: A (1,000 TU/mL) and B (10,000 TU/mL).
The 1-strength group received only 3 injections of 1 strength (B) 
of the grass pollen allergoid (0.1 mL of 1,000 TU, 0.3 mL of 3,000 
TU, and 0.6 mL of 6,000 TU) at a weekly interval. The standard 
group started with 1/10 of the dose of the 1-strength group and re-
ceived 7 injections (strength A: 0.1 mL of 100 TU, 0.2 mL of 200 
TU, 0.4 mL of 400 TU, and 0.8 mL of 800 TU; strength B: 0.15 mL 
of 1,500 TU, 0.3 mL of 3,000 TU, and 0.6 mL of 6,000 TU). When 
the maintenance dose had been reached, both groups received 2 
maximum-dose injections (0.6 mL of 6,000 TU) of strength B after 
14 and 28 days. After each SCIT injection, patients in both groups 
were supervised for at least 30 min. Dosage modification was per-
formed if local and/or systemic adverse events (AEs) occurred, and 
this was based on a predefined regime.
Assessment of AR and Asthma
To characterize AR severity, the investigator had to judge the 
severity grade according the criteria described in the ARIA guide-
lines [8] at the screening visits. Peak flow (PEF) measurements 
were also performed. Due to safety reasons, for all patients, these 
measurements were performed before and approximately 30 min 
after the SCIT injection. If a patient did not demonstrate a PEF of 
at least 70% before the injection, the injection was not given and 
the visit had to be rescheduled. The asthma status of all patients 
was monitored by the Asthma Control Questionnaire (ACQ) to 
ensure the control status and identify possible symptoms of undi-
agnosed asthma.
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Assessment of Safety and Tolerability End Points
The primary aim of the trial was to obtain information about 
the safety and tolerability of an accelerated dose escalation schedule 
for specific immunotherapy with the grass pollen allergoid. The 
analysis of AEs focused on treatment-emergent AEs (TEAEs), de-
fined as any AE that started or worsened after the first intake of 
trial medication until 30 days after the last administration of the 
investigational medicinal product (IMP) or trial-related procedure.
A systemic allergic reaction was defined as an AE related to the 
IMP and graded according to the WAO grading system based on 
the organ systems involved and the severity of the reaction.
The following descriptive safety variables were considered: the 
number, incidence, time of onset, type, and intensity of the AE as 
well as any serious AE assessed as being drug-related (by the inves-
tigator); the incidence and intensity of allergic systemic reactions 
after injections according to WAO grading; the number of patients 
reaching the maintenance dose without dose adjustment due to 
AEs; changes in laboratory values (hematology, clinical chemistry, 
and urinalysis) measured before and after the treatment phase; 
changes in vital signs and lung function measured before and after 
the treatment phase; the assessment of overall tolerability, by the 
investigator and the patient, using a 5-point Likert scale (1 = very 
bad; 5 = very good). The trial was supervised by an independent 
Data and Safety Monitoring Board.
Statistical Analysis
Due to the exploratory design of the trial, there was no formal 
estimation of sample size, accounting for the type I error rate, power, 
SD, and effect size. It was planned to randomize 35 patients per treat-
ment group, to guarantee a probability of 95% that AEs with a true 
incidence rate of 8.6% occur at least once in the treatment group.
The patients were assigned to the following sets before starting 
the analysis: the “All-Patients Set” (APS) comprised patients that 
gave their informed consent. The number of these patients equals 
the total number of screened patients. For this group, demograph-
ic data, the patient’s disposition, and reasons for premature trial 
termination are described. The “Safety Set” (SAF) was the group 
of patients who received at least 1 dose of trial medication. It is the 
basic analysis set for all assessments of safety and tolerability. For 
this set, exposure to AIT was analyzed.
Numbers and incidence rates of AEs and severe AEs related to 
the IMP, and the differences between these numbers and the inci-
dence rates of the 2 treatment groups are reported. For the inci-
dence rates, 95% confidence intervals (CIs) are also reported. AEs 
were analyzed separately for the dose escalation phase and the total 
treatment phase. The results of the tolerability assessments are pre-
sented as n (%) for each category as well as nonparametric statisti-
cal measures. Statistical tests for categorical variables (Fisher’s ex-
act test, χ2 test, and independent t test) were performed when ad-
equate. Otherwise, the analysis was performed descriptively, and 
explained by comparing events and frequencies between groups. 
For all statistical tests, a significance level of α = 5% was chosen.
Results
Trial Population
For this trial, 129 patients were screened, 87 were ran-
domized (1-strength group, n = 44; standard group, n = 
43), and 77 completed the trial (88.5%). One patient in 
the 1-strength group dropped out before the first SCIT 
injection due to flu-like symptoms. Therefore, 86 pa-
tients were eligible for the safety analysis. Due to the 
wrong dose allocation for 2 patients (both were initially 
randomized to the standard group but received the 
1-strength dose), the safety set comprised 45 patients in 
the 1-strength group and 41 in the standard group. Nine 
additional patients terminated the trial prematurely, 5 
from the 1-strength group and 4 from the standard group 
(Fig. 1). Two patients in the 1-strength group discontin-
ued the study because of TEAEs (1 for injection-site ery-
























Fig. 1. Disposition of patients. 1 Screening 
failures were due to not meeting inclusion 
and/or exclusion criteria, withdrawal of 
consent, or other reasons; 2 patient 205/007 
was not treated and discontinued already 
prior to the first dose of IMP; 3  patients 
207/003 and 207/006 were randomized to 
the standard group but received the 
1-strength treatment; 4 premature discon-
tinuations were due to AEs, withdrawal of 
consent, or other reasons; 5 patients were 
assigned to the SAF as treated; 6 completed 
patients are those patients who did not dis-
continue the trial prematurely. AE, adverse 
event; APS, All-Patients Set; disc., discon-
tinued; IMP, investigational medicinal 
product; SAF, Safety Set.
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the standard group. Other reasons for premature termi-
nation of the trial were the withdrawal of consent and 
protocol deviation (online suppl. Table S1; see www.
karger.com/doi/10.1159/000503684 for all online suppl. 
material).
The demographic and baseline characteristics were 
well balanced between the 2 groups (Table 1). Before treat-
ment, all patients experienced nasal symptoms and the 
majority of patients experienced eye symptoms (1-strength 
group: n = 35 [77.8%] vs. standard group: n = 33 [80.5%]). 
Wheeze, shortness of breath and cough was reported for 
about one-fifth of patients (range 18.6–22.1%) and chest 
tightness for 7.0%. Mean and median duration of symp-
toms were generally comparable between the groups, ex-
cept for chest tightness which had a shorter duration in 
the 1-strength group (mean 9.7 vs. 26.0 years; median 12.0 
vs. 21.0 years). Total IgE, specific IgE against grass pollen, 
specific IgG4 for P. pratense (Table 1) and other specific 
IgE values (i.e., birch, house dust mite, mugwort) did not 
differ significantly between groups. In the 1-strength 
group, 36/45 patients (80.0%), and in the standard group, 
39/41 patients (95.1%) reached the 1st AIT injection of the 
maintenance phase without a dose adjustment. Of the pa-
tients who did not reach the maintenance phase without 
a dose adjustment, 3 in the 1-strength group and 2 in the 
standard group experienced TEAEs that led to AIT reduc-
tion. The median treatment duration was 54.8 days in the 
1-strength group and 90.5 days in the standard group.








Mean (SD) 32.7 (9.44) 36.0 (12.21) 34.3 (10.91)
Median 33.0 36.0 33.0
Range 18–60 18–65 18–65
Gender, n (%)
Male 27 (60.0) 21 (51.2) 48 (55.8)
Female 18 (40.0) 20 (48.8) 38 (44.2)
Ethnicity, n (%)
White 44 (97.8) 40 (97.6) 84 (97.7)
American Indian or Alaskan Native 1 (2.2) 0 1 (1.2)
Asian 0 1 (2.4) 1 (1.2)
BMI, kg/m2
Mean (SD) 25.4 (4.00) 25.5 (6.04) 25.4 (5.05)
Median 25.0 23.9 24.7
Range 19–36 18–44 18–44
Smoking status, n (%)
Never 36 (80.0) 31 (75.6) 67 (77.9)
Ex-smoker 6 (13.3) 4 (9.8) 10 (11.6)
Current smoker 3 (6.7) 6 (14.6) 9 (10.5)
Pet contact, n (%)
No 35 (77.8) 32 (78.0) 67 (77.9)
Intermittent 0 2 (4.9) 2 (2.3)
Permanent 10 (22.2) 7 (17.1) 17 (19.8)
Total IgE
Median 150.00 224.00 166.00
Range 12.8–1326.0 9.7–3182.0 9.7–3182.0
Specific IgE for grass mix/earlybloom
Median 15.400 7.100 12.800
Range 0.36–100.00 1.17–100.00 0.36–100.00
Specific IgG4 for Phleum pratense
Median 0.340 0.240 0.325
Range 0.07–8.36 0.07–2.69 0.07–8.36
BMI, body mass index; Ig, immunoglobulin.
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Adverse Events
Overall, 72 (83.7%) patients reported at least 1 TEAE 
(Table 2). The proportion of patients with at least 1 TEAE 
during the trial was similar in both groups (1-strength 
group: 82.2%; standard group: 85.4%). All TEAEs (related 
or not related to AIT) are summarized in online supple-
mentary Table S2. Most of the reported TEAEs associated 
with AIT were local reactions at the injection site. There 
were 233 local reactions with a similar distribution in the 
2 groups (110 in the 1-strength group and 123 in the stan-
dard group). However, slightly more patients in the 
1-strength group experienced at least 1 local reaction 
(57.8 vs. 48.8%). Two patients in the 1-strength group ter-
minated the trial prematurely due to a TEAE. No deaths 
and no serious unexpected serious adverse reactions were 
reported during the trial.
All TEAEs assessed by the investigator as being linked 
to the AIT are summarized in Table 3. Overall, the most 
commonly reported local reactions were injection-site 
swelling (40.7% of patients, 87 TEAEs), followed by injec-
tion-site erythema (32.6% of patients, 79 TEAEs), and in-
jection-site pruritus (24.4% of patients, 50 TEAEs). Injec-
tion-site pain, injection-site warmth, injection-site hem-
orrhage, and injection-site urticaria were reported in 
≤5.8% of patients.
Of all reported 261 TEAEs related to AIT, most were 
of mild intensity (230 TEAEs, 88.1%) and occurred to a 
similar extent in both groups. Only 3 TEAEs related to 
AIT (1.1%) were classified as severe, and all 3 occurred in 
patients in the 1-strength group; 2 of them were reported 
in 1 patient and were also assessed as being serious.
Systemic Adverse Reactions
Overall, systemic allergic reactions occurred in 5 
(5.8%) patients, 4 (8.9%) in the 1-strength group and 1 
(2.4%) in the standard group. However, this difference 
was not statistically significant (p = 0.3629, two-sided 
Fisher’s exact test). Of 15 events reported overall, 14 oc-
curred in the 1-strength group. Events occurring more 
than once in at least 1 patient were rhinorrhea and dys-
pnea (both in 1 patient) and a decreased forced expira-
tory volume (3 events in 2 patients). All systemic allergic 
reactions were assessed as nonserious and no systemic 
TEAE with a WAO Grade > 2 was reported. A detailed 
analysis of the systemic allergic reactions revealed that 1 
trial site reported 11 of 14 systemic allergic reactions in 
the 1-strength group; this accounts for nearly 80% of the 
systemic allergic reactions in this group. These occurred 
only in 2 patients; one experienced 8 systemic allergic re-
actions and the other experienced 3. This result may be 
explained by a specific trial site effect which is discussed 
below. 
Time to Onset of TEAEs Related to AIT
No significant difference was observed in the time to 
onset after AIT administration between the 2 groups. 
Most of the TEAEs occurred in the first 2 h (online suppl. 
Table S3). However, the number of TEAEs in relation to 
individual AIT injection over the treatment period 
showed different patterns between the 2 groups. For the 
1-strength group, most TEAEs occurred after the first 
AIT injection, with a continuous decrease in the number 
of TEAEs along with further injections. In the standard 
group, the number of AIT-related TEAEs after the first, 
second, and third injection was low compared to the 
Table 2. Overview of TEAEs
Group 1 (n = 45) Group 2 (n = 41) Overall (n = 86)
n (%) e n (%) e n (%) e
TEAEs 37 (82.2) 200 35 (85.4) 244 72 (83.7) 444
TEAEs related to AIT 27 (60.0) 129 20 (48.8) 132 47 (54.7) 261
Local reactions 26 (57.8) 110 20 (48.8) 123 46 (53.5) 233
Systemic allergic reactions 4 (8.9) 14 1 (2.4) 1 5 (5.8) 15
Other type of events 3 (6.7) 5 3 (7.3) 8 6 (7.0) 13
TEAEs leading to discontinuation 2 (4.4) 2 0 0 2 (2.3) 2
Treatment-emergent SAE 1 (2.2) 2 0 0 1 (1.2) 2
Treatment-emergent SAE related to AIT 1 (2.2) 2 0 0 1 (1.2) 2
n (%) refers to patients who experienced at least 1 TEAE. e, number of events (TEAEs); AIT, allergen immu-
notherapy;  SAE, serious adverse event; TEAE, treatment-emergent adverse event.
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1-strength group, with the peak of TEAEs occurring after 
the fourth injection (Fig. 2).
Tolerability and Other Safety Parameters
Most of the investigators assessed overall tolerability 
at the end of the escalation phase as “very good” or “good” 
(68.4 and 26.3%, respectively). Similar results were ob-
tained in the patients’ assessment (53.9 and 40.8%, re-
spectively). The assessment results were similar in both 
groups (Fig. 3), with neither the statistical tests nor the 
CIs showing any statistically significant differences. Fur-
thermore, the investigators’ and patients’ assessments at 
the final visit revealed similar results. There were also no 
notable differences between the asthmatic and nonasth-
matic patients.
There were no clinically noteworthy changes in mean 
and median clinical chemistry, hematology, and urinaly-
sis values during the trial; the results were similar in the 2 
groups. The immunological profile was assessed at base-
line and at the final visit. During the course of the trial, 
the mean amount of IgG4 against Timothy grass pollen 
increased notably over time in both groups (Wilcoxon 
signed-rank test p < 0.0001). The comparison of the mean 
changes from baseline revealed no notable difference be-
tween groups at final visit (the van Elteren test: two-sided, 
p = 0.2552).
Discussion
Allergen-specific immunotherapy is the only treat-
ment that can modify the underlying course of the allergic 
diseases AR and allergic asthma [3, 4]. However, real-life 
compliance and adherence to AIT is limited by the long-
term updosing and maintenance phases [9]. Recently, 
Chaker et al. [6] demonstrated that an accelerated 4-dose 
escalation scheme can be administered with a favorable 
safety profile that is comparable to the standard 7-dose 
escalation regime.
Here, we were able to demonstrate that an accelerated 
high-dose escalation schedule with 1 strength for AIT 
with a grass pollen allergoid can be used in patients with 
AR with or without asthma, and that it has a safety and 
tolerability profile comparable to the standard escala-
tion schedule. Overall, 82.2% of patients reported at 
least 1 TEAE in the high-dose escalation group com-
Table 3. TEAE related to AIT and intensity of TEAEs
1-Strength (n = 45) Standard (n = 41) Overall (n = 86)
n (%) e n (%) e n (%) e
Overall 27 (60.0) 129 20 (48.8) 132 47 (54.7) 261
Mild 110 (85.3) 120 (90.9) 230 (88.1)
Moderate 16 (12.4) 12 (9.1) 28 (10.7)
Severe 3 (2.3) 0 3 (1.1)
General disorders and injection-site conditions 26 (57.8) 111 20 (48.8) 124 46 (53.5) 235
At the injection site
Swelling
21 (46.7) 49 14 (34.1) 38 35 (40.7) 87
Erythema 13 (28.9) 28 15 (36.6) 51 28 (32.6) 79
Pruritus 14 (31.1) 24 7 (17.1) 26 21 (24.4) 50
Pain 2 (4.4) 2 3 (7.3) 7 5 (5.8) 9
Warmth 3 (6.7) 5 0 0 3 (3.5) 5
Hemorrhage 1 (2.2) 1 1 (2.4) 1 2 (2.3) 2
Investigations 1 (2.2) 2 2 (4.9) 7 3 (3.5) 9
Forced expiratory volume decreased 1 (2.2) 2 1 (2.4) 1 2 (2.3) 3
Respiratory, thoracic, and mediastinal disorders 3 (6.7) 6 0 0 3 (3.5) 6
Nervous system disorders 1 (2.2) 1 1 (2.4) 1 2 (2.3) 2
Headache 1 (2.2) 1 1 (2.4) 1 2 (2.3) 2
Skin and subcutaneous tissue disorders 2 (4.4) 3 0 0 2 (2.3) 3
n (%) refers to patients who experienced at least one TEAE. e, number of events (TEAEs); AIT allergen immunotherapy; IMP, in-
vestigational medicinal product; TEAE, treatment-emergent adverse event.
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Fig. 3. Assessment of overall tolerability in 
the 2 groups by the investigator (a, b) and 
the patient (c, d) after the last dose of the 
escalation phase on a 5-point Likert scale 
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pared to 85.4% in the standard dose escalation group in 
this multicenter, open-label, randomized phase II trial. 
Of note, the majority of patients in the high-dose escala-
tion group (80.0%) reached the first AIT injection of the 
maintenance phase without any dose adjustment. Of 
those patients who did not reach the maintenance phase 
without dose adjustment, only 3 patients in the high-
dose escalation group had TEAEs that led to an AIT dose 
reduction.
A slightly higher number of patients in the high-dose 
escalation group than in the standard dose escalation 
group had systemic allergic reactions (n = 4 [8.9%] vs. 
n = 1 [2.4%]), but these were all classified as being WAO 
Grade 1 or 2. As outlined above, analysis of these events 
revealed that nearly 80% of the systemic allergic reac-
tions in the high-dose escalation group were reported in 
only 2 patients from 1 trial site. We are therefore of the 
opinion that this result could be explained by a specific 
trial site effect. This interpretation is supported by the 
finding that for 1 of these 2 patients, injection-site he-
matoma was also described, which could indicate an in-
correct AIT administration that then led to greater oc-
currence of systemic allergic reactions. Indeed, specific 
reevaluation of the administration technique at this 
study site revealed an incorrect injection technique. In 
summary, a higher number of systemic allergic reactions 
does not necessarily indicate an accumulation due to the 
accelerated dose escalation scheme, but rather points to 
a specific trial site effect in combination with incorrect 
AIT handling.
Recently, Tophof et al. [10], in a noninterventional, 
prospective, observational, longitudinal study, assessed 
the incidence of local and systemic side effects of SCIT in 
581 pediatric patients and 10,015 injections. The inci-
dence of the observed immediate local side effects was as 
high as in studies on adult patients receiving SCIT [11]. 
A total of 54.6% of the patients experienced immediate 
local side effects at least once; immediate and delayed sys-
temic adverse reactions occurred in 2.2 and 7.4% of pa-
tients, respectively. The number of local and systemic 
AEs was comparable to the high-dose escalation group in 
our study population [10].
The time to onset of TEAEs after the AIT injections 
was similar in both groups in our clinical trial. However, 
a different pattern was observed with respect to the asso-
ciation of AEs and the individual injections. For example, 
the highest number of AEs in the high-dose escalation 
group occurred after the first injection. In contrast, AEs 
peaked in the standard dose escalation group after the 
fourth injection. Comparing the cumulative amounts of 
the AIT products, this peak was observed at a dosage of 
about 1,000 TU. Hypothetically, these data might point 
towards faster tolerance induction in the high-dose esca-
lation group. Besides the aspects of safety, tolerability, 
and adherence to therapy, this would be an additional 
argument to escalate updosing in AIT. However, this is 
only a hypothesis derived from clinical observation which 
must still be confirmed with immunological data.
Recently, Pfaar et al. [12] initiated intraseasonal grass-
pollen AIT with an 8-day updosing regime and observed 
significant differences in the immunological response as 
early as week 3, with an increase in IgE-blocking factor 
and IgG4 levels. We observed a significant increase in spe-
cific IgG4 antibodies against P. pratense in both groups. 
As the final blood sample was drawn at the last trial visit, 
which took place on different days in the 2 groups (day 50 
vs. day 90), no direct comparison can be made based on 
our data with respect to the kinetics of the IgG4 response.
Slightly more patients in the high-dose escalation 
group discontinued the trial prematurely (6 vs. 4). How-
ever, only 3 patients dropped out of the trial due to AEs; 
1 reported an AE prior to the first dose, and the other 2 
(both in Group I) terminated the trial prematurely due to 
restlessness and severe injection-site erythema accompa-
nied by severe injection-site swelling, respectively. Obvi-
ously, additional data in larger cohorts are necessary for 
the confirmation of the overall good safety profile in our 
high-dose escalation group.
In conclusion, our results show that, regardless of dos-
ing schedule, AIT with this grass pollen allergoid was safe 
and well-tolerated in patients with AR or rhinoconjunc-
tivitis with or without comorbid asthma. TEAEs with the 
high dose and standard dose escalation were comparable, 
mild or moderate in intensity, and assessed as nonserious 
in all but 1 patient.
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